Bioverativ Inc. (BIVV) Reaches $49.97 Formed H&S; Convergys (CVG)’s Sentiment Is 0.93

December 7, 2017 - By Vivian Park

Convergys Corporation provides customer management services to communications and media, technology, financial services, retail, and healthcare industries in North America and internationally. The company has market cap of $2.19 billion. The firm offers solutions across the customer lifecycle, including sales, customer service, technical support, customer retention, and collection services; and solutions in contact center technology comprising multichannel interaction, cross-channel integration framework, real-time decisioning engine, robotic process automation, intelligent notification, campaign management, personalized care, personalized selling, agent productivity, and retention solutions. It has a 16.72 P/E ratio. It also provides analytics and consulting, and software solutions, including integrated customer experience analytics, post-contact surveys, relational loyalty research, customer segmentation and profiling, call elimination analysis, analysis of customer effort, digital channel optimization, and integrated contact center analytics solutions, as well as voice of customer SaaS software for measuring customer satisfaction.

Bioverativ Inc. (BIVV) formed H&S with $48.47 target or 3.00% below today’s $49.97 share price. Bioverativ Inc. (BIVV) has $5.41B valuation. The stock decreased 1.41% or $0.72 during the last trading session, reaching $49.97. About 23,892 shares traded. Bioverativ Inc. (NASDAQ:BIVV) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 2 analysts covering Bioverativ (NASDAQ:BIVV), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Bioverativ has $58 highest and $41 lowest target. $49.50’s average target is -0.94% below currents $49.97 stock price. Bioverativ had 2 analyst reports since February 2, 2017 according to SRatingsIntel. As per Thursday, February 2, the company rating was initiated by Morgan Stanley. As per Thursday, February 2, the company rating was initiated by Gabelli.

Analysts await Bioverativ Inc. (NASDAQ:BIVV) to report earnings on January, 25. BIVV’s profit will be $53.01M for 25.49 P/E if the $0.49 EPS becomes a reality. After $0.63 actual earnings per share reported by Bioverativ Inc. for the previous quarter, Wall Street now forecasts -22.22% negative EPS growth.

Since January 1, 0001, it had 0 buys, and 2 insider sales for $484,951 activity.

Horrell Capital Management Inc. holds 4.34% of its portfolio in Convergys Corporation for 310,000 shares. Fort Washington Investment Advisors Inc Oh owns 5.71 million shares or 2.14% of their US portfolio. Moreover, Zpr Investment Management has 2.1% invested in the company for 57,705 shares. The Kansas-based Dean Capital Management has invested 1.7% in the stock. Lathrop Investment Management Corp, a Arkansas-based fund reported 265,417 shares.

Analysts await Convergys Corporation (NYSE:CVG) to report earnings on February, 28. They expect $0.45 earnings per share, down 4.26% or $0.02 from last year’s $0.47 per share. CVG’s profit will be $41.58 million for 13.15 P/E if the $0.45 EPS becomes a reality. After $0.42 actual earnings per share reported by Convergys Corporation for the previous quarter, Wall Street now forecasts 7.14% EPS growth.

The stock decreased 0.38% or $0.09 during the last trading session, reaching $23.67. About 7,604 shares traded. Convergys Corporation (CVG) has declined 10.85% since December 7, 2016 and is downtrending. It has underperformed by 27.55% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Vivian Park




Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: